ReviewJournal of the Korean Association of Oral and Maxillofacial Surgeons2023
Review of two immunosuppressants: tacrolimus and cyclosporine.
Review in Journal of the Korean Association of Oral and Maxillofacial Surgeons, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Efficacy of tacrolimus versus cyclosporine after lung transplantation: an updated systematic review, meta-analysis, and trial sequential analysis of randomized controlled trials.European journal of clinical pharmacology · 2024Pooled it
- Alleviation of Allergic Rhinoconjunctivitis Symptoms in Participants Treated with a 0.005% Tacrolimus Eye-Drop Solution.Clinical ophthalmology (Auckland, N.Z.) · 2024Trial
- Altered SIgA-targeting of gut microbiota is associated with long-term dysbiosis in pediatric solid organ transplant recipients.Gut microbes · 2026Article
- Topical framework nucleic acid transdermal delivery system for reprogramming cutaneous dendritic cells to maintain graft immune homeostasis.Bioactive materials · 2026Article
- Inhibition of Janus kinase/signal transducer and activator of transcription reduces nociceptive sensitization in a murine model of complex regional pain syndrome.Pain reports · 2026Article
- Microarray Gene Expression Analysis of Lesional Skin in Canine Vesicular Cutaneous Lupus Erythematosus (VCLE).Veterinary dermatology · 2026Article
- Tacrolimus-Associated Adverse Effects After Liver Transplantation: A Narrative Review.Journal of clinical medicine · 2026Review
- Carcinogenic Medications: A Review of Specific Agents and Molecular Mechanisms of Carcinogenesis.Cancer reports (Hoboken, N.J.) · 2026Review
- Post-Transplant Tremor: Characteristics and Differences Based on Sex and Post-Transplant Therapy.Neurology international · 2026Article
- Optimization of the Missouri Osteochondral Preservation System for the storage of peripheral nerve allografts.JPRAS open · 2026Article
- Advances in Pathophysiology and Therapeutic Paradigm Shifts in Chronic Spontaneous Urticaria: A Narrative Review.Dermatology and therapy · 2026Review
- Calcium signaling in psoriasis: from pathogenesis to therapeutic opportunities.Frontiers in immunology · 2026Review
- Kidney adverse events associated with calcineurin inhibitors: a real-world study based on the FAERS database and network pharmacology.Frontiers in medicine · 2026Article
- Comparative neuropsychiatric safety signals of tacrolimus versus cyclosporine in solid organ transplantation: ten-year FAERS pharmacovigilance study.Frontiers in immunology · 2026Article
- Hepatitis C Direct-Acting Antivirals in the Immunosuppressed Host: Mechanisms, Interactions, and Clinical Outcomes.Viruses · 2025Review
- Tacrolimus modulates the PI3K AKT mTOR pathway in retinal epithelial cells under inflammatory stress.Scientific reports · 2025Article
- Acute Severe Ulcerative Colitis (ASUC): Clinical Features, Initial Management, and the Role of Advanced Therapies.Biomedicines · 2025Review
- From bench to bed: deep insights the tacrolimus-induced diabetes and gut microbiota dysbiosis.European journal of medical research · 2025Review
- In Vitro and In Vivo Testing of Decellularized Lung and Pancreas Matrices as Potential Islet Platforms.International journal of molecular sciences · 2025Article
- Tacrolimus Modulates TGF-β Signaling-Related Genes and MicroRNAs in Human Retinal Pigment Epithelial Cells Activated by Lipopolysaccharide.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunosuppressants are vital in organ transplantation including facial transplantation (FT) but are associated with persistent side effects. This review article was prepared to compare the two most used immunosuppressants, cyclosporine and tacrolimus, in terms of mechanism of action, efficacy, and safety and to assess recent trials to mitigate their side effects. PubMed and Google Scholar queries were conducted using combinations of the following search terms: "transplantation immunosuppressant," "cyclosporine," "tacrolimus," "calcineurin inhibitor (CNI)," "efficacy," "safety," "induction therapy," "maintenance therapy," and "conversion therapy." Both immunosuppressants inhibit calcineurin and effectively down-regulate cytokines. Tacrolimus may be more advantageous since it lowers the likelihood of acute rejection, has the ability to reverse allograft rejection following cyclosporine treatment, and has the potential to reinnervate nerves. Meanwhile, graft survival rates seem to be comparable for the CNIs. To avoid nephrotoxicity, various immunosuppressants other than CNIs have been studied. Despite averting nephrotoxicity, these medications show increases in acute rejection or other types of adverse effects compared to CNIs. FT has been a topic of interest for oral and maxillofacial surgeons, and the postoperative usage of immunosuppressants is crucial for the long-term prognosis of FT. As contemporary transplantation regimens incorporate novel medications along with CNIs, further research is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.